October 1, 2019 / 6:17 AM / in 6 months

AstraZeneca's combo lung disease therapy falls short of FDA approval

Oct 1 (Reuters) - The U.S. Food and Drug Administration declined to approve AstraZeneca Plc's combo therapy to treat a form of lung disease, the drugmaker said on Tuesday.

AstraZeneca said that it will work closely with the FDA regarding next steps, including submitting results from an additional late-stage study, which was not completed at the time the marketing application was submitted to the health regulator. (Reporting by Aakash Jagadeesh Babu in Bengaluru; Editing by Bernard Orr)

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below